<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778596</url>
  </required_header>
  <id_info>
    <org_study_id>CST-L-1</org_study_id>
    <nct_id>NCT00778596</nct_id>
  </id_info>
  <brief_title>Prednisolone Priming Study in Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yun-Fan Liaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study purpose:&#xD;
&#xD;
      To investigate whether ALT rebound following corticosteroid priming enhances response to&#xD;
      telbivudine therapy.&#xD;
&#xD;
      Efficacy assessments:&#xD;
&#xD;
      The primary endpoint will be the 1-year HBe-Ag seroconversion rate with or without&#xD;
      prednisolone priming.&#xD;
&#xD;
      Data analysis:&#xD;
&#xD;
      A summary table will be presented as frequency tables for categorical variables as number,&#xD;
      and percentage, whereas descriptive tables for continuous variables as number, mean ± SD and&#xD;
      median (minimum, maximum). All statistical assessments will be two-sided and evaluated at&#xD;
      significance level of 0.05. Continuous variables will be analyzed using t-test, or ANOVA, and&#xD;
      categorical variables will be analyzed using chi-square or Fisher's exact test. A&#xD;
      non-parametric method, Wilcoxon rank-sum or sign-rank tests will be conducted for continuous,&#xD;
      and categorical variables if data is far from normal distribution.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IV, multi-center, double-blinded, placebo control randomized study to&#xD;
      evaluate the therapeutic effect of telbivudine with or without prednisolone priming in&#xD;
      patients with chronic hepatitis B.&#xD;
&#xD;
      Patients are allocated to either group A or B randomly.&#xD;
&#xD;
      Group A: Patients initially receive a 4-week course of oral prednisolone (30 mg daily for 3&#xD;
      weeks and then 15 mg daily of 1 week). After a rest period of no treatment for 2 weeks, the&#xD;
      patients receive telbivudine therapy at a daily dose of 600 mg for 2 years. Patients will be&#xD;
      asked to come back to clinic for follow-up 6 months after telbivudine treatment.&#xD;
&#xD;
      Group B: Patients receive a 4-week course of placebo. After a rest period of no treatment for&#xD;
      2 weeks, the patients receive telbivudine therapy at a daily dose of 600 mg for 2 years.&#xD;
      Patients will be asked to come back to clinic for follow-up 6 months after telbivudine&#xD;
      treatment.&#xD;
&#xD;
      Eligible patients will be randomized prior to the first dose of study medication. The visit&#xD;
      at which the patient receives the first dose will be defined as the study Baseline. Patients&#xD;
      will return to the clinic at 3, 4, 6, 10, 14, 18, 30, 44, 58, 72, 86, 98, 110, 116, 122, 128&#xD;
      and 134 weeks post-Baseline. At each of these visits, routine clinical laboratory tests,&#xD;
      adverse event inquiry, and other clinical assessments will be performed. Serum samples for&#xD;
      HBV DNA analysis will be obtained at 4, 6, 30, 58, 86, 110 and 134 weeks. Serum samples for&#xD;
      HBV sequencing will be obtained at Screening and Week 110 (or upon early termination from the&#xD;
      study).&#xD;
&#xD;
      Complete physical examinations will be performed at each study visits to evaluate any adverse&#xD;
      signs or symptoms reported by the patient.&#xD;
&#xD;
      Serum for HBeAg, antibody to HBeAg (HBeAb), HBsAg, and antibody to HBsAg (HBsAb) will be&#xD;
      obtained at Screening, Baseline, and Weeks 6, 30, 58, 86, 110 and 134(or upon early&#xD;
      termination from the study), and at all protocol-required follow-up visits.&#xD;
&#xD;
      Patients will be followed monthly for 6 months after discontinuation of study drug(s).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be the 1-year HBe-Ag seroconversion rate with or without prednisolone priming.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Prednisolone priming</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisolone priming 4 weeks, then treated with telbivudine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo priming</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo priming for 4 weeks, then followed a telbivudine treatment for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.</description>
    <arm_group_label>Prednisolone priming</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo priming</intervention_name>
    <description>Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.</description>
    <arm_group_label>Placebo priming</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Treatment naïve patients or interferon-treated patients 6 months before, or oral&#xD;
             antiviral agents treatment ≦ 2 weeks before or treatment &lt; 3 months 1 year prior to&#xD;
             screening.&#xD;
&#xD;
          2. Male or female, 18 to 65 years of age.&#xD;
&#xD;
          3. Documented chronic hepatitis B defined by all of the following:&#xD;
&#xD;
               -  Clinical history compatible with compensated chronic hepatitis B.&#xD;
&#xD;
               -  Detectable serum hepatitis B surface antigen (HBsAg) &gt;6 months and at the&#xD;
                  screening visit.&#xD;
&#xD;
               -  Hepatitis B e antigen (HBeAg) positive &gt;3 months.&#xD;
&#xD;
               -  Serum HBV DNA &gt; 2x10^5 IU/mL and raised serum ALT &gt; 2xULN but &lt; 5xULN determined&#xD;
                  on at least 2 occasions 1 month apart before screen or within 3 months of&#xD;
                  pre-screen, raised serum ALT &gt; 2xULN but &lt; 5xULN determined 1 month apart before&#xD;
                  screen and at screen.4.&#xD;
&#xD;
          4. Liver biopsy showing chronic hepatitis and fibrosis stage ≦ 4 by Ishak classification&#xD;
             within 6 months or fibrosis ≦ 4 between 6 to 12 months plus platelet count ≧&#xD;
             150,000/mm3 or noninvasive assessment (fibroscan or ARFI) of liver fibrosis to&#xD;
             excluding liver cirrhosis within 6 months.&#xD;
&#xD;
          5. Willing and able to comply with the study drug regimen and all other study&#xD;
             requirements.&#xD;
&#xD;
          6. Willing and able to provide written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded from the study for any of the following reasons:&#xD;
&#xD;
          1. Pregnant or nursing.&#xD;
&#xD;
          2. Of reproductive potential (men and women) and unwilling to use double-barrier method&#xD;
             of contraception (i.e., condom with spermicide or diaphragm with spermicide).&#xD;
&#xD;
          3. Co-infection with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV.&#xD;
&#xD;
          4. History or clinical signs/symptoms of hepatic decompensation or portal hypertension,&#xD;
             such as ascites, presence of esophageal varices or variceal bleeding, hepatic&#xD;
             encephalopathy, or spontaneous bacterial peritonitis.&#xD;
&#xD;
          5. Liver cirrhosis (Ishak fibrosis score 5 or 6).&#xD;
&#xD;
          6. Any medical condition that requires prolonged or frequent use of systemic acyclovir or&#xD;
             famciclovir (e.g., for recurrent herpes virus infections).&#xD;
&#xD;
          7. History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, such&#xD;
             as suspicious foci on imaging studies or elevated serum alpha-fetoprotein (AFP)&#xD;
             levels. A history of treated malignancy other than HCC is allowable if the patient's&#xD;
             malignancy has been in complete remission, off chemotherapy and without additional&#xD;
             surgical intervention, during the preceding 3 years.&#xD;
&#xD;
          8. One or more known primary or secondary causes of liver disease other than hepatitis B&#xD;
             (e.g., alcoholism, non-alcoholic steatohepatitis, autoimmune hepatitis, malignancy&#xD;
             with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's&#xD;
             disease, other congenital or metabolic conditions affecting the liver, congestive&#xD;
             heart failure or other severe cardiopulmonary disease). Gilbert's syndrome and&#xD;
             Dubin-Johnson syndrome will not exclude patients from participation in this trial.&#xD;
&#xD;
          9. History of clinically evident pancreatitis.&#xD;
&#xD;
         10. Currently abusing alcohol (i.e., an average daily intake of more than 40 g of ethanol)&#xD;
             or illicit drugs or a history of alcohol abuse or illicit substance abuse within the&#xD;
             preceding 2 years. Patients currently on methadone maintenance treatment programs are&#xD;
             NOT eligible.&#xD;
&#xD;
         11. A medical condition that requires frequent or prolonged use of systemic&#xD;
             corticosteroids (e.g., severe asthma, severe arthritis or autoimmune conditions, organ&#xD;
             transplantation, adrenal insufficiency).&#xD;
&#xD;
         12. A medical condition requiring the chronic or prolonged use of potentially hepatotoxic&#xD;
             drugs (dapsone, erythromycin, fluconazole, ketoconazole, rifampin, anti-tuberculosis&#xD;
             regimens, etc.). All such drugs must have been discontinued ≥ 30 days prior to&#xD;
             randomization.&#xD;
&#xD;
         13. A medical condition requiring use of nephrotoxic drugs (e.g., aminoglycosides,&#xD;
             amphotericin B, foscarnet, vancomycin, cyclosporine, tacrolimus, or frequent&#xD;
             nonsteroidal anti-inflammatory drugs (NSAIDS) or aspirin [administered daily for more&#xD;
             than one week at a scheduled dose intended for anti-inflammatory therapy]). All such&#xD;
             drugs must have been discontinued ≥ 30 days prior to randomization.&#xD;
&#xD;
         14. Any other concurrent medical or psychosocial condition likely to preclude compliance&#xD;
             with the schedule of evaluations in the protocol or likely to confound the efficacy or&#xD;
             safety observations of the study.&#xD;
&#xD;
         15. Enrolled or planning to enroll in another clinical trial of an investigational agent&#xD;
             while participating in this study.&#xD;
&#xD;
         16. Any of the following laboratory values at Screening:&#xD;
&#xD;
               -  Hemoglobin (Hb) &lt;11 mg/dL for men or &lt;10 mg/dL for women.&#xD;
&#xD;
               -  Total white blood cell count (WBC) &lt;2,500/mm3.&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt;1,500/mm3.&#xD;
&#xD;
               -  Platelet count &lt;75,000/mm3.&#xD;
&#xD;
               -  Serum albumin &lt;3.2 g/dL.&#xD;
&#xD;
               -  Total bilirubin ≥2 mg/dL with direct bilirubin &gt; 50% of total bilirubin.&#xD;
&#xD;
               -  Serum creatinine &gt;1.0 x ULN.&#xD;
&#xD;
               -  Alpha-fetoprotein (AFP) &gt;50 ng/mL (requires further evaluation, to rule-out&#xD;
                  hepatocellular carcinoma)&#xD;
&#xD;
               -  Creatinine clearance (CrCl) &lt;0.83 mL/sec (&lt;50 mL/min) calculated by the&#xD;
                  laboratory using the modified Cockcroft-Gault method.&#xD;
&#xD;
               -  Serum amylase or lipase ³1.5 x ULN.&#xD;
&#xD;
               -  Prothrombin time (PT) prolonged by &gt;3 seconds or International Normalized Ratio&#xD;
                  (INR) &gt; 1.5, based on the upper limits of normal (ULN) of the reference value,&#xD;
                  despite vitamin K administration.&#xD;
&#xD;
         17. Use of any investigational drugs within 30 days or 5 half-lives of randomization,&#xD;
             whichever is longer.&#xD;
&#xD;
         18. Systemic malignancy within 5 years.&#xD;
&#xD;
         19. Previous treatment with telbivudine.&#xD;
&#xD;
         20. History of hypersensitivity to components of either telbivudine formulations, or to&#xD;
             drugs with similar chemical structures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun-Fan Liaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mei-Hsia Ku, MS</last_name>
    <phone>+886-3-3281200</phone>
    <phone_ext>8114</phone_ext>
    <email>kuvicky1029@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Chiayi</name>
      <address>
        <city>Chiayi County</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-Ching Chuang, BS</last_name>
      <phone>+886-5-3621000</phone>
      <phone_ext>2005</phone_ext>
    </contact>
    <investigator>
      <last_name>Shui-Yi Dong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Kaohsiung</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chiu-Rong Chen, BS</last_name>
      <phone>+886-7-7317123</phone>
      <phone_ext>8301</phone_ext>
    </contact>
    <investigator>
      <last_name>Chuan-Mo Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Keelung</name>
      <address>
        <city>Keelung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Ling Chen, BS</last_name>
      <phone>+886-2-24313131</phone>
      <phone_ext>3181</phone_ext>
    </contact>
    <investigator>
      <last_name>Rong-Nan Chien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Linkou, Taoyuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei-Hsia Ku, MS</last_name>
      <phone>+886-3-3281200</phone>
      <phone_ext>8114</phone_ext>
      <email>kuvicky1029@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yun-Fan Liaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <last_update_submitted>May 24, 2012</last_update_submitted>
  <last_update_submitted_qc>May 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Yun-Fan Liaw</investigator_full_name>
    <investigator_title>Yun-Fan Liaw</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Telbivudine</keyword>
  <keyword>Prednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

